Brainscope

BrainScope is a leading neurotechnology company advancing brain health through objective, AI-powered insights derived from brain electrical activity (EEG). Its proprietary platform analyzes EEG data from any source using advanced machine and deep learning to deliver rapid, radiation-free, accessible and cost-effective biomarkers - greatly expanding the clinical utility of traditional EEG. BrainScope's device for head injury assessment was the first device in neurology cleared by the FDA under the AI/Machine Learning-Enabled Medical Device category. BrainScope has commercialized its first set of FDA-cleared biomarkers for mild brain injury assessment (both brain bleeds and concussions) with remarkable outcomes in major U.S. health systems, which include ~50% reduction in unnecessary head CTs, substantial reductions in patient length of stay in emergency departments, and high utility for concussion clinics, personal injury cases and sports. The company is now advancing novel biomarkers for early Alzheimer’s detection, ARIA assessment, rapid stroke evaluation, concussion subtyping, military blast exposure, and others.